Bamforth John Philip 4

What Happened
Director John Philip (John P.) Bamforth received a grant of derivative securities (an 80,000-share award/option) from Humacyte, Inc. on June 11, 2026. The filing reports an acquisition price of $0.00 (this reflects the award/grant reporting; it is a derivative award rather than an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely filing).
• Transaction type/code: A (award/grant); reported as a derivative security.
• Amount: 80,000 shares (derivative). Reported acquisition price: $0.00.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote (vesting/exercisability): First 25% of the option becomes exercisable on June 11, 2027; thereafter 1/48 of the option vests/exercisable on the 11th of each month through June 11, 2030.
• No indication of 10b5-1 plan, tax withholding, immediate sale, or late filing in this report.

Context
This is a standard equity award to an insider (director). As a derivative/option grant, the award does not convert into shares or cash until it vests and the options are exercised; there is no immediate sale or proceeds reported. Grants can be part of regular compensation and do not by themselves indicate buying or selling sentiment.